Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and

potential molecules by Nebbioso, M et al.
 International Journal of 
Molecular Sciences
Review
Therapeutic Approaches with Intravitreal Injections
in Geographic Atrophy Secondary to Age-Related
Macular Degeneration: Current Drugs and
Potential Molecules
Marcella Nebbioso 1,* , Alessandro Lambiase 1 , Alberto Cerini 1, Paolo Giuseppe Limoli 2,
Maurizio La Cava 1 and Antonio Greco 1
1 Department of Sense Organs, Faculty of Medicine and Odontology, Umberto I Policlinic, Sapienza
University of Rome, p. le A. Moro 5, 00185 Rome, Italy; alessandro.lambiase@uniroma1.it (A.L.);
cerinialberto@hotmail.it (A.C.); maurizio.lacava@uniroma1.it (M.L.C.); antonio.greco@uniroma1.it (A.G.)
2 Low Vision Research Centre of Milan, Piazza Sempione 3, 20145 Milan, Italy; paololimoli@libero.it
* Correspondence: marcella.nebbioso@uniroma1.it; Tel.: +39-06-49975422; Fax: +39-06-49975425
Received: 10 February 2019; Accepted: 1 April 2019; Published: 4 April 2019


Abstract: The present review focuses on recent clinical trials that analyze the efficacy of
intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD),
such as neuroprotective drugs, and complement inhibitors, also called immunomodulatory or
anti-inflammatory agents. A systematic literature search was performed to identify randomized
controlled trials published prior to January 2019. Patients affected by dry AMD treated with
intravitreal therapeutic agents were included. Changes in the correct visual acuity and reduction in
geographic atrophy progression were evaluated. Several new drugs have shown promising results,
including those targeting the complement cascade and neuroprotective agents. The potential action
of the two groups of drugs is to block complement cascade upregulation of immunomodulating
agents, and to prevent the degeneration and apoptosis of ganglion cells for the neuroprotectors,
respectively. Our analysis indicates that finding treatments for dry AMD will require continued
collaboration among researchers to identify additional molecular targets and to fully interrogate the
utility of pluripotent stem cells for personalized therapy.
Keywords: age-related macular degeneration; anti-inflammatory agents; complement inhibitors; dry
AMD; geographic atrophy; intravitreal injection; neuroprotective agents; non-exudative AMD
1. Introduction
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the
elderly population, and it is defined as a chronic, multifactorial, and progressive central retinal
disease. The prevalence of AMD is approximately 8.69% in the worldwide population and 12.3%
in Europe [1]. There were 8.4 million AMD patients with moderate to severe vision impairment
in 2015 with probable increases to 196 million in 2020 [1]. Macular pigmentation changes in the
chorioretinal layers and the drusen are present at the early stage of AMD, while the advanced stages
are characterized by dry and/or neovascular forms [1,2]. Choroidal neovascularization (CNV) in AMD,
often accompanied by serum-hemorrhagic retinal detachment, eventually leads to the degeneration
of photoreceptors [2,3]. Likewise, in dry AMD or non-exudative AMD, and then subsequently in
geographic atrophy (GA), there are areas of progressive atrophy and thinning mainly involving the
layers of the retinal pigment epithelium (RPE) and the underlying choriocapillaris; these modifications
are a prelude to the degeneration of photoreceptors leading to irreversible loss of visual function [2–4]
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(Figure 1). The main risk factors for GA are ageing, family history, cigarette smoking, cardiovascular
risk factors, previous cataract surgery, etc. [3]. Thus, the characteristics of GA with progressive and
irreversible loss of retinal cells inevitably are responsible for around 20% of cases of legal blindness [1–4].
No effective treatment for GA is currently available, unlike neovascular AMD in which anti-angiogenic
treatments are effective in improving visual acuity [4]. Inflammation, complement activation, oxidative
stress, blood flow regulation, and reduced neuroprotection are the main pathways implicated in the
progression of GA [3,4]. Currently, the only preventive option for dry AMD is the Age-Related Eye
Disease Studies (AREDS) formulation, which reduces the risk of AMD progression [5]. The etiology
of AMD is believed to be the result of a combination of oxidative stress, chronic inflammation,
predisposing genetic and environmental factors. Oxidative stress, responsible for the production of
retinal reactive oxygen species (ROS), can induct chronic inflammation and programmed necrosis
in RPE cells. It is thus triggered by excessive presence of photosensitizing factors, intensive oxygen
metabolism, and polyunsaturated fatty acids [6]. Genetic polymorphism has been associated with
AMD disease and implies the involvement of inflammation factors, lipid metabolism, angiogenesis,
and RPE dysfunction [7]. This article focuses on actual, or still ongoing, clinical trials evaluating the
efficacy of intravitreal therapies in dry AMD, such as neuroprotective drugs, complement inhibitors,
immunomodulatory or anti-inflammatory agents.
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Figure 1. Imaging of geographic atrophy (GA). -face and B-scan spectral-d main ptical coherence
tomography (SD-OCT). Decreased macular thi e s (center marker 89/78 µm), retinal pigment
epithelial (RPE) irregularities, and of the underlying choriocapillaris. The atrophic area shows
hyperreflective clumps at different levels, segmented plaques of the outer band and elevations with
variable reflectivity. GA is a form of advanced dry age macular degeneration (AMD). An eye may have
uni- or multi-focal atrophic lesions, which, when summed, determine the central total lesion area. Scale
bars = 200 µm.
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2. Methods
Our systematic literature search was conducted in PubMed, Embase, Cochrane Library, and
Web to identify randomized controlled trials published prior to January 2019. The search keywords
were: “age-related macular degeneration”, “atrophic”, “dry”, “current drugs”, “geographic atrophy”,
“non-exudative”, “intravitreal injections”, and “potential molecules”. The patients dry AMD treated
with intravitreal therapeutic agents were included. The changes in the correct visual acuity (BCVA) and
the reduction in GA progression were evaluated. We also studied reviews, comments, and disquisitions
on the pathology.
3. Main Pathogenetic Pathways in Dry AMD: Complement Dysfunction and Inflammation
The therapies target different aspects of GA, including inflammatory pathways, oxidative stress
RPE degeneration, byproducts of the visual cycle, restoration of choroidal perfusion, use of growth
factors (GFs), modification of cellular DNA through genetic therapy, and replenishing RPE cells with
stem cell-derived RPE cells [6–9]. It has been hypothesized that anti-inflammatory agents could
represent a therapeutic option [8]. In fact, chronic inflammation is reported to play an important role
in early AMD pathogenesis.
The deposition of intracellular drusen in the RPE layer, containing cell debris and proteins
such as complement components, triggers the inflammatory response [7,8]. The disease progresses,
consequently, with sustained inflammatory response, further drusen accumulation and oxidative stress,
resulting in damage and eventually cell death. Immunohistochemical examination of drusen shows
many proinflammatory proteins including apolipoprotein E, acute phase proteins, coagulation proteins,
β-amyloid (Aβ), and complement activation components during the development of the disease [7–9].
The complement cascades in its various forms, classical, alternative and mannose-binding lectin,
converge on a final single pathway via the cleavage of complement factor C3 into C3a and C3b that
leads to phagocytosis, inflammation, formation of a membrane attack complex (MAC) and ultimately
to cell death [9] (Scheme 1).
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Scheme 1. Diagram outlining the complement pathways. Three pathways of complement activation:
classical, lectin, and alternative. MBL: mannose-binding lectin; MASP: MBL-associated serine proteases,
MASP-1, and MASP-2.
The alternative pathway has been implicated in the pathogenesis of the disease; in particular,
complement components 2, 3, and 7 have shown to be associated with AMD. The formation of MAC
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consequent to the activation of the complement pathway causes cell lysis and chemokine release, thus,
causing the recruitment of inflammatory cells and the increase of vascular permeability [9]. Hence,
the inhibition of the overactive complement pathway represents a viable therapeutic approach to
arrest the progression of GA. Moreover, there is an interest in the role of immune dysfunction, such as
inappropriate complement cascade activation, in the etiology of AMD. Knowledge of the major role
that complement cascade activation plays in the disease has led to several therapeutic options [9–12].
In summary, we know that numerous proteins and polypeptides have therapeutic effects in the
treatment of degenerative diseases, but localized treatment of retinal diseases is complicated by the
blood-retinal barrier that hinders the penetration of several molecules from the circulatory blood
system to the neurosensory retina [3,4]. Therefore, the intravitreal injection (IVI), without systemic
exposure, could be the simplest and most useful route to allow an adequate chorioretinal restoration
and preserve vision [3,4]. The present review will focus on neuroprotective, and immunomodulatory,
or anti-inflammatory agents that have been used for IVI in patients with GA (Figure 2). A summary of
relevant clinical trials is presented in Table 1.
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Figure 2. The intravitreal injection (IVI) is a procedure to place a medication directly into the vitreous
cavity. IVIs are used to administer medications in various retinal conditions. Representation of
molecules, neuroprotective, immunomodulatory or anti-inflammatory agents, which have been used for
IVIs in patients with geographic atrophy (GA). MBL: mannose-binding lectin; MASP: MBL-associated
serine proteases, MASP-1, and MASP-2; sTCC: soluble terminal complement complex; MAC: membrane
attack complex.
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Table 1. Summary of the clinical trials for the intravitreal injections (IVIs) of geographic atrophy (GA).
Target Drug Action of the Drug Studies Authors
Neuroprotectors
Brimonidine Tartrate; α2 adrenergic
receptor agonist
Prevents RGCs death via the
non-amyloidogenic Aβ-pathway
NCT00658619 (2011) Ph1; NCT02087085 (2019) Ph2
(Beacon Allergan Inc., Dublin, Ireland)
Nizari, et al., 2016 [13];
Doozandeh, et al., 2016 [14]
Ciliary neurotrophic factor; Encapsulated cell
technology (ECT) and NT-501 implant
Member of the IL-6 family of neuropoietic
cytokines, prevents photoreceptors
degeneration
NCT00063765 (2006) Ph1; NCT00447954 (2009)
Ph2; NCT00447993 (2009) Ph2; NCT00447980
(2010) Ph2 (Neurotech Pharmaceuticals,
Cumberland, RI, USA)
Zhang, et al., 2011 [15];
Lambert, et al.2001 [16];
Thanos, et al., 2004 [17];
Kauper, et al., 2012 [18]
Immune modulating
antinflammatory or
complement inhibitors
Lampalizumab; Humanized
monoclonal antibody
Inhibits complement factor D (CFD)–mediated
activation and amplification of the alternative
complement pathway
NCT01229215 (2013) Ph2 Mahalo; NCT02247479
(2018) Ph3 Chroma; NCT02247531 (2018) Ph3
Spectri (Genentech/Roche, South San Francisco,
CA, USA)
Do, et al., 2014 [19];
Yaspan, et al., 2017 [20];
Holz, et al., 2018 [21]
Zimura (ARC-1905); Single strand
nucleic acid aptamer
Inhibits the cleavage of C5 and prevents the
formation of the membrane attack complex
(MAC)
NCT00950638 (2012) Ph1; NCT03362190 (2018)
Ph2/3; NCT02686658 (2018) Ph2
(Ophthotech/Archemix, New York, NY, USA)
Hariri, et al., 2015 [22];
Wei, et al., 2018 [23];
Drolet, et al., 2016 [24];
Sun, et al., 2015 [25]
APL-2; POT-4/AL-78898A; Synthetic cyclic
peptide; conjugated to polyethylene glycol
polymer. It is a modified version of POT-4
designed to have longer half-life
Binds to C3 blocking all three pathways of
complement activation
NCT000473928 (2017) Ph1; NCT02503332 (2018) Ph
2 Filly; NCT03525613 (2022) Ph3 Oaks;
NCT03525600 (2022) Ph3 Derby (Apellis
Pharmaceuticals Inc., Crestwood, KY, USA)
Kassa, et al., 2019 [26]
POT-4; AL-78898A. Cyclic peptide Inhibits complement pathways and preventMAC formation
NCT00473928 (2010) Ph1 (Alcon Inc., Fort Worth,
TX, USA)
Kaushal, et al., 2009 [27];
Singer, et al., 2014 [28]
CLG561; Inhibitor of properdin Stabilizes the alternative pathway C3 andC5 convertases
NCT01835015 (2016) Ph1; NCT02515942 (2018)
Ph2; (Novartis, Basel, Switzerland; and Alcon Inc.,
Fort Worth, TX, USA)
Kassa, et al., 2019 [26];
Ricklin, et al., 2016 [29]
LFG316; Tesidolumab; Human IgG1 Inhibits the complement system
NCT01255462 (2011) Ph1; NCT02515942 (2018)
Ph2; NCT01527500 (2018) Ph2 (Novartis
Pharmaceuticals, Basel, Switzerland,)
Kassa, et al., 2019 [26];
Ricklin, et al., 2016 [29];
Sagar, et al., 2017 [30]
Suppressors of
inflammation Iluvien; Fluocinolone acetonide; Corticosteroid
Vasoconstriction, release of inflammatory
mediators, mitotic activity, suppression of
membrane permeability, and immune response
NCT00695318 (2013) Ph2 (Alimera Sciences,
Alpharetta, GA, USA) Taskintuna, et al., 2016 [31]
Anti-oxidative stress Risuteganib; Anti-Integrin; Luminate(Alg-1001)
Downregulates oxidative stress and restores
homeostasis
NCT03626636 Ph2 (Allegro Ophthalmics, LLC,
San Juan Capistrano, CA, USA) Kaiser, 2017 [32]
Other treatment
modalities AAVCAGsCD59; HMR59; Ocular gene therapy
Gene therapy expressing C59 complement
factor. Soluble recombinant version of the
CD59 inhibiting the formation of the MAC
NCT03144999 Ph1 (Hemera Biosciences, Waltham,
MA, USA)
Clinicaltrials.gov;
No Authors [33]
Novel Compounds RO7171009; RG6147 Undefined mechanism NCT03295877 Ph1 (Genentech/Roche,South San Francisco, CA, USA)
Clinicaltrials.gov;
No Authors [34]
RGCs: retina ganglion cells; Aβ: β-amyloid; Ph1, Ph2, Ph3: phase of the clinical trial (1, 2, or 3); IL-6: interleukin-6; C: complement; IgG1: immunoglobulin G1.
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4. Potential Therapeutic Molecules in Dry AMD
4.1. Neuroprotective Agents Designed to Prevent Retinal Ganglion Cell Apoptosis
4.1.1. Brimonidine
Brimonidine is a selective α2 adrenergic (α2A) receptor agonist that has been used for its
pressure-lowering effects in the treatment of glaucoma for several years. Its mechanism in lowering
the intraocular pressure involves both the decrease of aqueous humor production and increased
uveoscleral outflow [13]. No significant side effects are known, although an excess of drowsiness
and lethargy have been reported as side effects in small patients [35]. In animal models it was
found that brimonidine protects photoreceptors, bipolar cells, and retinal ganglion cells from a
variety of retinal insults, including retinal phototoxicity and retinal ischemia. The authors state that
neuroprotection is achieved via different mechanisms such as the release of brain-derived neurotrophic
factor (BDNF) from retinal ganglion cells and by upregulation of cell survival signaling pathways [36].
Importantly, brimonidine has been demonstrated to be neuroprotective via the modulation of Aβ
toxicity. This pathway is strongly implicated in neurodegenerative conditions such as Alzheimer’s
disease and in glaucoma-related models. Aβ is the major constituent of senile plaque and may,
therefore, play a key role in the stress–response to induce cellular apoptosis, even though, to this day, a
comprehensive mechanism is not fully understood [13].
Nizari et al. proposed a model of α2A agonists’ neuroprotective effect against Aβ toxicity [13].
Aβ is associated with abnormal processing of amyloid precursor protein (APP). APP can be
metabolized into soluble APPα (sAPPα) by the non-amyloidogenic pathway or into Aβ by
the amyloidogenic pathway; α2A receptor agonists have been reported to negatively affect the
amyloidogenic pathway, preventing the excitotoxicity mediated by glutamate and, therefore, cell
death. Moreover, α2A receptor agonists can also affect APP processing via the extracellular matrix, by
modulating matrix metalloproteinase-9 (MMP-9) and laminin through laminin-binding protein (LBP),
preventing further toxic interactions with Aβ and by increasing the processing of APP into sAPPα,
promoting the non-amyloidogenic pathway. Furthermore, α2A receptor agonists can also increase
levels of phosphorylated arabinose-inducible BAD promoter (P-Bad), thereby promoting cell survival
and neuroprotection [13,14]. The initial results of a study (Clinicaltrials.gov: NCT00658619) involving
119 participants demonstrated that IVIs of 200 µg or 400 µg of brimonidine produced a significant
reduction in GA size when compared to the sham arm. In particular, the 200 µg dose produced a
reduction in GA size by 18% while the 400 µg dose produced a 27% reduction. No significant adverse
effects have been reported for either injections [14].
A larger phase 2 trial of 310 patients is currently underway (Beacon, NCT02087085). It is a
double-blind, sham-control study with its primary outcome being the changes in size of GA lesion
from baseline to 24 months [14]. Participants were randomized to receive either 400 µg sustained
release solid brimonidine tartrate implant administered intravitreally on day one then every 3 months
through month 21 or sham via needleless applicator. This clinical trial is expected to end in 2019.
4.1.2. Ciliary Neurotrophic Factor
Ciliary neurotrophic factor (CNTF) is a neurotrophic factor member of the interleukin-6 (IL-6)
family of neuropoietic cytokines. It influences the survival and differentiation of cells in the nervous
system, including retinal cells, although the function of CNTF is not fully understood [37].
Its activities are mediated through a heterotrimeric complex formed by a specific α subunit
CNTF receptor (CNTFRα) and two β subunits, leukemia inhibitory factor receptor (LIFRβ) and IL-6
signal transducer (gp130). CNTF is able to delay the loss of cells during retinal degeneration by
protecting the photoreceptors in 12 animal models [37]. The treatment with CNTF targets Müller
glia in order to trigger a cascade of signaling events leading to photoreceptor survival. CNTF
activates complex molecular and cellular responses in numerous cell types. Exposure to high levels of
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CNTF regulates photoreceptor specific genes, particularly those associated with phototransduction.
This could profoundly influence neuronal characteristics and chorioretinal function.
Delivery of CNTF to the retina is a major challenge: encapsulated cell technology (ECT) and
the NT-501 implant were developed in some studies [38]. The implant was developed to deliver the
drug directly to the retina over a sustained period. The availability of the protein is assured by a
stable and long-term secretion that also allows a continuous exposure of the target site. Preliminary
results involving the NT-501 ECT implant appear promising, demonstrating sustained, safe and
efficacious delivery of the protein therapy of up to several years in the eye. ECT is a system consisting
of human cell lines that are genetically engineered to endogenously express a selected therapeutic
protein at a regulated delivery rate [15–17,38,39]. Many studies on animal models have demonstrated
the possibility of using CNTF as an approach to reduce photoreceptor cell loss. Between February and
October 2007, 51 patients with GA were enrolled and randomly assigned to phase 1 and 2 of the studies
to evaluate the effect on retinal structure and function (NCT00063765, NCT00447954, NCT00447980,
NCT00447993) [15,18]. Patients were randomly assigned to receive a high-dose implant, a low-dose
implant or sham surgery in one eye at the ratio of 2:1:1. All patients completed the 12-mo endpoint,
and no patients dropped out of the study. While in the high- or low-dose CNTF groups a statistically
significant difference in total macular volume was found, compared to baseline at all-time points
(months 4, 6, and 12) (p < 0.001), instead no variation appeared in the sham one [17,37]. In particular,
the high-dose group had a more remarkable outcome than the low-dose at all-time points (p < 0.05).
As shown by cross-sectional evaluation of high-resolution line scans, these results were linked to an
increased width of the external layer complex. The GA area varied slightly among the 3 groups at
baseline, but the difference was not statistically significant. Although no improvement in visual acuity
was observed in the three groups, an increase in retinal thickness maintained during the whole follow
up period (12 mo, p < 0.001) was observed in the groups treated with CTNF implants. The result has
been reported to be dose-dependent with better response in high-dose patients. The observed increase
in retinal thickness was associated with visual acuity stabilization regardless of baseline BCVA in
high-dose patients [15,18].
4.2. Immune Modulating or Anti-Inflammatory Agents
4.2.1. Lampalizumab
Lampalizumab, previously referred to as anti-complement factor D antibody, anti-factor D,
FCFD4514S, RG7417, RO 5490249, or TNX-234, is an antigen-binding fragment (Fab) of a humanized
monoclonal antibody (mAb) directed against complement factor D (CFD). Lampalizumab selectively
inhibits the activation mediated by the CFD of the alternative complement pathway. Lampalizumab
does not act on the classical or mannose-binding lectin pathways of the complement activation [19].
The Mahalo phase 2 clinical trial (NCT01229215) investigated the efficacy of IVIs of lampalizumab
in patients with GA. Moreover, the trial examined both the safety and the pharmacokinetics of
lampalizumab [20]. This trial enrolled 120 patients, and it demonstrated an acceptable safety profile
during the 18-month treatment period. Monthly lampalizumab treatment demonstrated a 20%
reduction in lesion area progression versus sham control. A more substantial benefit from the monthly
treatment (44% reduction in GA area progression compared to control) was observed in a subgroup
of complement factor I (CFI) risk-allele carriers (57% of the patients analyzed were CFI risk-allele
carriers). The Mahalo study, published in 2013, showed a potential effect of the treatment in patients
with GA and supported therapeutic targeting of the alternative complement pathway for treating AMD
pathogenesis [20]. Between August 2014, and October 2016, 906 Chroma (GX29176; NCT02247479)
participants and 975 Spectri (GX29185; NCT02247531) participants randomly underwent sham
injections every 4 weeks (153 Chroma and 161 Spectri, respectively), lampalizumab every 4 weeks
(298 Chroma and 330 Spectri, respectively), sham every 6 weeks (152 Chroma and 160 Spectri,
respectively), or lampalizumab every 6 weeks (303 Chroma and 324 Spectri, respectively) [21]. Both the
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Chroma and Spectri phase 3 trials showed no significant difference in GA progression during the
whole follow period between sham and lampalizumpab treated arms [21].
4.2.2. Zimura
Zimura (ARC-1905) is a polyethylene glycol (PEG), oligonucleotide, chemically synthesized single
strand nucleic acid aptamer that targets and inhibits complement factor C5. The inhibition of C5 in
the complement cascade prevents the formation of key terminal fragments (C5a and C5b-9). C5b-9 is
involved in the formation of the MAC, which causes cellular death through the disruption of the
cell membrane [22–24]. A phase 1 trial for dry AMD (NCT00950638), started in 2009, was completed
in 2012. It evaluated the safety and tolerability of intravitreous Zimura injections. Forty-seven
participants, 50 years or older, with GA secondary to dry AMD in both eyes were recruited. The study
completed with no results posted. The phase 2a trial (NCT03362190) evaluated the safety profile
of Zimura administered intravitreally in combination with 0.5 mg of Ranibizumab, in 65 wet AMD
patients who had not previously been administered an anti-vascular endothelial GF (VEGF) drug [25].
A considerably higher percentage of patients receiving the Ranibizumab–Zimura combination showed
improved visual acuity compared with controls of patients receiving Ranibizumab monotherapy. Later,
in October 2018, Ophthotech completed patient enrolment (estimated 120 patients) in its phase 2b
clinical trial to evaluate the safety and efficacy of Zimura compared to sham injection in subjects
with autosomal recessive Stargardt disease 1. The company has decided to modify its ongoing
phase 2/3 clinical trial of Zimura monotherapy in 200 participants with GA secondary to dry AMD
(NCT02686658). The trial has been adjusted to accelerate the deadline by reducing the number of
patients, shortening the time for attaining the primary efficacy endpoint and thereby reducing the cost
to complete the study. Estimated primary completion date is November 2019 [25].
4.2.3. POT-4 and APL-2
POT-4 is a cyclic peptide comprising 13 amino acids derived from compstatin, which irreversibly
binds to C3 and prevents its proteolytic activation to C3a and C3b; thus, inhibiting the complement
pathways and preventing MAC formation. It forms a gel when injected at high concentrations into
the vitreous. A phase I clinical trial (NCT00473928) in wet AMD patients was completed in 2010
without safety concerns at doses up to 1.05 mg [27,28,40]. The potent inhibition of this drug on the
complement could increase the risk of endophthalmitis; therefore, it is necessary to establish the
appropriate safety dose [40]. APL-2 is a modified version of POT-4 designed to have a longer half-life.
APL-2 (POT-4/AL-78898A) is a synthetic cyclic peptide conjugated to a PEG polymer that binds
specifically to C3, effectively blocking all three pathways of complement activation: classical, lectin, and
alternative [26]. It has undergone phase 1 and 2 trials (NCT00473928, NCT02503332), and it showed no
safety concerns. A multicenter, randomized, single-masked, sham-controlled clinical phase 2 research
project, named the Filly trial, was carried on 246 patients with GA, at over 40 clinical sites, located in
the United States, Australia, and New Zealand. APL-2 was injected as IVI monthly for 12 months, and
the patients were followed for an extra period of 18 months [26]. Apellis Pharmaceuticals reported
that APL-2, after a 12 month follow-up, determined a reduction in the GA growth rate. Every month
injection reduced the GA growth rate by 29%, while every other month injection reduced GA growth
rate by 20% when compared to the sham arm. After the 12-month period, subjects were followed
for a further six months without treatment. During this period of non-treatment, the GA lesions
in the previously treated groups grew at a rate similar to sham. Subjects previously treated with
monthly APL-2 showed only a 12% reduction over the six-month period compared to sham, while
those previously treated with every other month APL-2 showed a 9% reduction compared to sham.
Two AMD phase 3 clinical trials, Oaks and Derby (NCT03525613-NCT03525600), are being initiated for
the development of APL-2 in the treatment of GA secondary to advanced AMD in 600 participants
each. A multi-center, randomized, double-masked, sham-controlled study to compare the efficacy and
safety of intravitreal APL-2 therapy with sham injections the subject population will consist of subjects
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with GA secondary to AMD: patients’ recruitment is still ongoing, and the estimated study completion
date is December 2022 [26].
4.2.4. CLG561
CLG561 is an inhibitor of properdin. It acts to stabilize the alternative pathway C3 and C5
convertases by extending the half-lives of the C3 and C5 converting enzymes; based on human
genetics as well as pathophysiological features of AMD that implicate complement activation [26].
A phase 1 study (NCT01835015) has ended in 2016; it has evaluated the safety, tolerability, and serum
pharmacokinetics of CLG561 in subjects with AMD. A phase 2 study (NCT02515942) started on 2015
enrolling 114 participants, to evaluate the safety and efficacy of 12 (every 28 days) IVIs of CLG561 as
a monotherapy and in combination with LFG316 as compared to sham in subjects with GA [26,41].
The study was completed, but the reporting date is on August 2020.
4.2.5. LFG316
LFG316, or Tesidolumab, is a fully human IgG1 targeting complement factor C5 that inhibits the
complement system activation [26,29,41]. A clinical phase 1 dose-escalation and safety study with
single IVIs of 0.15–5mg LFG316 were performed in patients with GA or choroidal neovascularization
due to AMD (NCT01255462). No adverse effects have been published and the drug was well tolerated.
A phase 2 study (NCT02515942) started on 2015 enrolling 114 participants, to evaluate the safety
and efficacy of 12 (every 28 days) IVIs of CLG561 in combination with LFG316 and CLG561 as a
monotherapy and compared to sham in subjects with GA [29,30,42]. The studies were completed,
but the reporting date is on August 2020. In a clinical trial phase 2 testing low doses of LFG316
(NCT01527500), 158 participants with GA were treated. The study was divided into 2 parts: part A
evaluated the safety and efficacy of multiple 5 mg/50 µL doses of IVI LFG316 against sham every
28 days for 505 days and part B evaluated the safety and pharmacokinetics of a single IVI dose of
10 mg/100 µL of LFG316. At the completion of the trial, LFG-316 was found to have an acceptable
safety profile, but was not effective in reducing GA lesion growth rate or improving visual acuity.
4.2.6. Suppressors of Inflammation: Iluvien
Iluvien is a sustained-release formulation of fluocinolone acetonide. It is a corticosteroid,
a synthetic hydrocortisone derivative [31]. The fluorine substitution at position 9 in the steroid
nucleus greatly enhances its activity. It is only approved for the treatment of diabetic macular edema
(DME). Iluvien could slow the progression of GA. A total of 40 patients affected bilaterally by GA were
recruited in a phase 2 study (NCT00695318). The study was completed, but the results are not yet
available [31].
4.3. Anti-Oxidative Stress
Risuteganib (Luminate)
Risuteganib (Alg-1001) is an anti-integrin that downregulates oxidative stress and restores
homeostasis. It localizes for several months in the RPE after the IVI giving luminate the potential
to block the four pathways of oxidative stress. Alg-1001 targets three integrin receptors that are
implicated in dry AMD in order to restore homeostasis in the retina. It aims to regulate oxidative stress
before it has a chance to initiate multiple pathways of tissue damage. Currently, no phase 2 study
results have been posted on a randomized controlled, double-masked, crossover clinical trial designed
to evaluate the safety and exploratory efficacy of Risuteganib (1.0 mg), injected intravitreally, on
eligible subjects who have been diagnosed with intermediate non-exudative AMD (Clinicaltrials.gov.
NCT03626636) [32].
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4.4. Other Treatment Modalities
Ocular Gene Therapy: AAVCAGsCD59
AAVCAGsCD59 (HMR59) is a potential IVI gene therapy for patients with GA, delivered via
adeno-associated viral expression. The aim is to increase the expression of a soluble recombinant
version of the naturally occurring CD59 (sCD59). sCD59 is designed to protect retinal cells by inhibiting
the formation of the MAC, the terminal step of complement-mediated cell lysis. In gene therapy, the
cells of the retina are permanently altered to produce sCD59 for whole duration of the patient’s
life. With gene therapy a single injection of AAVCAGsCD59 is needed for the drug to be effective.
The open-label and multi-center study of phase 1 will evaluate safety in 17 participants with additional
8 patients enrolled for 24 months. The 3 groups were divided according to 3 single intravitreal
administrations at low, medium and high dosage in an office setting from March 2017 (NCT03144999).
Currently, no study results have been posted on Clinicaltrials.gov [33].
4.5. Novel Compounds Derived from High-Throughput Drug Screens
RO7171009
RO7171009 or RG6147 is an investigational drug being evaluated for the potential treatment of GA
secondary to AMD. The mechanism of action is yet undefined. The safety and tolerability of RO7171009
following single and multiple IVI administrations in patients with GA will be the object of an extra
investigation through a phase 1, open-label, multicenter study. Currently, the study (NCT03295877) is
composed of two levels of single-dose escalation (SAD), and multiple-dose (MD) stages in 28 patients.
The examined results will be tolerability, safety, rate of adverse events, and serum concentration of
RO7171009. The study ended on November 2018, and participants are no longer being examined or
treated. Currently, no study results have been posted on Clinicaltrials.gov [34].
5. Discussion
There are still no treatments that slow progression of dry AMD. Ongoing clinical trials continue
to pursue new drugs for the purpose of preventing and/or treating dry AMD, although some intitially
promising complement pathway inhibitors (such as lampalizumab) have failed to achieve expected
outcomes in clinical trials, a number of compelling prospects remain [13–31,35–42]. Currently, APL-2,
which binds the C3 protein blocking all three pathways of complement activation, may be the most
promising molecule [26–28,40,41]. The clinical trials Oaks and Derby, enrolling 600 patients each and
ongoing at 58 different locations, will be completed in 2022 [26–28,40]. Similarly, we are awaiting the
results on brimonidine, a neuroprotective agent, which will be published in 2019 [13,14].
No statistically significant improvement in visual acuity was observed across treatment
groups using NT-501 ECT implantation to deliver CNTF via genetically engineered human
cells [15–18,38,39]. It is possible to speculate that these molecules might be more effective
if injected in the initial phases of the macular degeneration, especially because they act as
neuroprotectors or immunomodulating/anti-inflammatory agents. We know that the mechanism of
action of the neuroprotectors is to prevent degeneration and apoptosis of ganglion cells whilst the
mechanism of action for the immunomodulating agents is to block the complement cascade model.
The pharmacological association, alternating the IVIs during the administration of the therapeutic
protocol, could be useful for the different mechanism of action of the two classes of molecules.
The main issue the researchers are called to resolve is when to start the treatment of dry AMD
patients. We should be sure not to start too early to avoid aggressive therapies, nor too late for the high
risk of losing most of the healthy tissue. Moreover, during more advanced stages of the pathology, new
genetic therapies could be able to block the biomolecular dysfunction inducing the death of retinal
cells. In the late stages, after the development of GA and cell death in the macular area, only new
therapies using staminal cells might be able to regenerate lost tissues.
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We hypothesize that distinguishing different stages of dry AMD is critical for establishing
guidelines to employ the most effective therapeutic strategy for each patient [43–46].
Retinal morphological changes might be used to identify patients early in the course of AMD
development who might still be at a reversible phase of the disease and, therefore, amenable to
intervention. Minimum sizes to define atrophic areas vary; the commonly used Wisconsin Grading
System includes lesions ≥175 µm in diameter. The definitions of non-exudative AMD in the
international statistical classification of diseases are in Table 2 [46–51]. A recent consensus of retina
international experts strongly recommends multimodal imaging to measure and classify the different
forms of neovascular and non-neovascular-AMD [52]. So, color fundus photography, confocal fundus
autofluorescence, confocal near-infrared reflectance, and high-resolution optical coherence tomography
volume scans should be acquired at regular intervals throughout the clinical studies [52]. The use of
the different therapies depending on the stage might avoid a consequent severe visual loss in old age.
In light of these considerations, we would like to recall our research in which subjects affected
by GA have been treated with eye drops based on nerve GF (NGF) [53], or with autologous stem
cell transplantation [54–56]. It has been ascertained, through the Regen Lab SA of tissue engineering
in Switzerland (Swiss Biotech Association, available online: https://www.swissbiotech.org/), that
the autograft produces numerous neurotrophic and angiotrophic GFs determining a beneficial
impact in terms of visual acuity and retinal sensitivity, evaluated with microperimetry and ocular
electrophysiology [55–59].
Table 2. Definitions of dry age-related macular degeneration (AMD) or non-exudative AMD in the
international classification of diseases (ICD), and clinical modification (CM) according to the World
Health Organization (WHO).
Definitions of Dry AMD or Non-Exudative AMD According to the WHO
World Health Organization
(WHO). ICD-10 2016 [47]. Centers
for Disease Control (CDC).
International Classification of
Diseases, Clinical Modification
(ICD-10-CM): 2016 [48]
World Health Organization (WHO). ICD-11
Beta Draft (Mortality and Morbidity
Statistics); 2017 [49]
American Academy of Ophthalmology
(AAO). ICD10-CM: subspecialty ICD-10
decision trees and guides; 2016 [50]. Centers
for Disease Control (CDC). International
Classification of Diseases, Tenth Revision,
Clinical Modification (ICD-10-CM): 2017 [51]
Non-exudative AMD
Any AMD with no choroidal
neovascularization, including
early, intermediate AMD, and
geographic atrophy (GA)
Initial dry AMD
Combination of multiple small drusen,
some medium drusen (diameter
63–124 µm), or retinal pigment epithelial
(RPE) irregularities
Initial AMD
Numerous small drusen (≤63 µm), some
medium drusen (>63 and ≤124 µm), or RPE
irregularities.
Progressive dry AMD Medium drusen, one
or more large drusen (diameter 125 µm), or
GA without involvement of the fovea
Progressive dry AMD
Extensive medium drusen (>63 and
≤124 µm), or 1 or more large druse (>125 µm)
Terminal GA
GA involving the center of the fovea
Advanced GA
GA not involving the center of the fovea
Terminal Geographic Atrophic
GA involving the center of the fovea
6. Conclusions
The future of dry AMD is one in which the most appropriate and personalized treatment will be
employed for each patient. To this end, we expect that future studies resulting in successful clinical
trials will entail collaborations between researchers studying disparate approaches to dry AMD.
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